• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Hyperammonemic Encephalopathy Resulting From Intravenous Valproate for Status Epilepticus
【24h】

Hyperammonemic Encephalopathy Resulting From Intravenous Valproate for Status Epilepticus

机译：由静脉丙戊酸钠引起的癫痫持续状态的高氨血症性脑病

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The FDA approved vaiproate sodium injection (iv VPA) for seizure management in patients unable to receive oral VPA. Subsequent studies confirming the safety of rapid infusion of iv VPA led to investigations of its use for status epilepticus. Intravenous vaiproate has been suggested as an alternative to phenytoin and/or phenobarbital in patients with hypersensitivity to or at high risk for the sedative or vasoactive effects of these drugs, or for seizure types more likely to respond to vaiproate (e.g. absence).' Hyperammonemic encephalopathy is a well-recognized complication of oral valproate. This may be common during introduction of VPA, as one case series of 38 patients reported 8 patients acutely manifesting confusion, somnolence and elevated ammonia. We report 2 cases of acute encephalopathy with hyperammonemia following iv VPA for status epilepticus.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号